Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy trial targets blinding eye disease

NCT ID NCT06018558

First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 17 times

Summary

This study tests a new gene therapy called OCU410 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The trial involves up to 60 participants aged 50 and older and aims to check the treatment's safety and whether it can slow or stop the disease. The therapy is given as an injection under the retina.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • A) Retina Foundation of the Southwest

    Dallas, Texas, 75231, United States

  • Advanced Research, LLC

    Coral Springs, Florida, 33067, United States

  • Associated Retina Consultants

    Phoenix, Arizona, 85020, United States

  • B) Retina Consultants of Texas

    Bellaire, Texas, 77401, United States

  • Duke Eye Center

    Durham, North Carolina, 27710, United States

  • Gundersen Health System

    La Crosse, Wisconsin, 54601, United States

  • Mid Atlantic Retina

    Cherry Hill, New Jersey, 08034, United States

  • Miidwest Eye Institute

    Carmel, Indiana, 46290, United States

  • Mississippi Retina Associates

    Jackson, Mississippi, 39202, United States

  • The Retina Institute

    St Louis, Missouri, 63128, United States

  • The University of Pittsburgh

    Pittsburgh, Pennsylvania, 15260, United States

  • Valley retina Institute

    McAllen, Texas, 78503, United States

Conditions

Explore the condition pages connected to this study.